Shares of Bausch Health Companies Inc. (BHC), formerly known as Valeant Pharmaceuticals International Inc., are up 35% since the start of this year.
Anchiano Therapeutics, formerly known as Biocancell, is a clinical-stage biotechnology company developing a targeted gene therapy to improve the standard treatment for early-stage bladder cancer.
Shares of BioTelemetry Inc. (BEAT) have been hitting new highs, thanks to the string of strong quarterly results. The stock closed at an all-time high of $76.50 yesterday, and that represents a gain of 30% in just a month.
Harpoon Therapeutics, Inc. is a clinical-stage an immuno-oncology company, and its proprietary antibody-based drug discovery platform is called TriTAC, which offers a new way to unleash the target cell-killing properties of a patient's own immune system.
Shares of Assembly Biosciences Inc. (ASMB) are down nearly 69% from their 52-week high of $67.36 recorded on March 13, 2018.
Shares of AVROBIO Inc. (AVRO) have lost 39% of their value over the last 1 month in sharp contrast to the iShares Nasdaq Biotechnology ETF (IBB) index which has gained 8% during the same period.
Shares of Innoviva Inc. (INVA), which recently touched a new 52-week high of $19.82, are up 12% so far this month, slightly lagging behind the iShares NASDAQ Biotechnology Index (ETF) (IBB), which has gained 14% during the same period.
Axonics Modulation Technologies Inc. (AXNX), which recently made its debut on the NASDAQ, is down nearly 2% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) has gained nearly 8% for the same period.
Starpharma (SPHRY.OB), on Thursday, announced that it has licensed the sales and marketing rights of VivaGel BV in the United States to ITF Pharma, a subsidiary of Italfarmaco S.p.A, a privately held European specialty pharmaceutical company.
2018 has been a banner year for healthcare IPOs in the U.S. - with more than 80 companies making a debut on the bourses compared to 50 in 2017. Let's take a look at some of the healthcare IPOs of 2018 that have delivered more than 50% returns.
Achillion Pharmaceuticals Inc. (ACHN), which is slated to report clinical data next week, has gained 7% so far this month.
Osmotica Pharmaceuticals plc (OSMT), which recently made its debut on the Nasdaq, is down 12% since its IPO while the iShares Nasdaq Biotechnology ETF (IBB) index has lost nearly 5% of its value for the same period.
Shares of Catalyst Pharmaceuticals Inc. (CPRX) have lost 26% of their value so far this year while the iShares Nasdaq Biotechnology ETF (IBB) has fallen about 2.6% during the same period.
Shares of Gamida Cell Ltd. (GMDA) are up nearly 15% this month while the iShares Nasdaq Biotechnology ETF index (IBB) is down 1.55% for the same period.
Of late, cannabis-related news and stocks have been garnering a lot of investor attention. Let's take a look at some of them.